Patents by Inventor Gerhard Johann

Gerhard Johann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized anti-CD73 antibodies
    Patent number: 11859007
    Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: January 2, 2024
    Assignees: CORVUS PHARMACEUTICALS, INC., BIOATLA, INC.
    Inventors: Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 11827704
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 28, 2023
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
    Publication number: 20230013364
    Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 19, 2023
    Inventors: Glenn Dranoff, Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20230000964
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 5, 2023
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • METHODS OF USING ALS INHIBITOR HERBICIDES FOR CONTROL OF UNWANTED VEGETATION IN ALS INHIBITOR HERBICIDE TOLERANT BETA VULGARIS PLANTS
    Publication number: 20220275391
    Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.
    Type: Application
    Filed: May 12, 2022
    Publication date: September 1, 2022
    Inventors: Ruediger HAIN, Gerhard JOHANN, Guenter DONN
  • Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
    Patent number: 11413340
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 16, 2022
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Methods of using ALS inhibitor herbicides for control of unwanted vegetation in ALS inhibitor herbicide tolerant beta vulgaris plants
    Patent number: 11371057
    Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 28, 2022
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ruediger Hain, Gerhard Johann, Guenter Donn
  • COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3
    Publication number: 20220153835
    Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: September 30, 2021
    Publication date: May 19, 2022
    Inventors: Glenn DRANOFF, Frederic TRIEBEL, Chrystelle BRIGNONE, Walter A. BLATTLER, Jennifer Marie MATARAZA, Catherine Ann SABATOS-PEYTON, Hwai Wen CHANG, Gerhard Johann FREY
  • ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
    Publication number: 20210284737
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 16, 2021
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • HUMANIZED ANTI-CD73 ANTIBODIES
    Publication number: 20210253727
    Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
    Type: Application
    Filed: September 24, 2020
    Publication date: August 19, 2021
    Inventors: Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
  • ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
    Publication number: 20210009687
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: June 9, 2020
    Publication date: January 14, 2021
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to PD-L1 and methods of treating cancer
    Patent number: 10851165
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: December 1, 2020
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • Humanized anti-CD73 antibodies
    Patent number: 10822426
    Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 3, 2020
    Assignees: CORVUS PHARMACEUTICALS, INC., BIOATLA, LLC
    Inventors: Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20200339689
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 10752687
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 25, 2020
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody molecules to LAG-3 and uses thereof
    Patent number: 10711060
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 14, 2020
    Assignees: NOVARTIS AG, Immutep S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • METHODS OF USING ALS INHIBITOR HERBICIDES FOR CONTROL OF UNWANTED VEGETATION IN ALS INHIBITOR HERBICIDE TOLERANT BETA VULGARIS PLANTS
    Publication number: 20200095602
    Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 26, 2020
    Inventors: Ruediger HAIN, Gerhard Johann, Guenter Donn
  • Methods of using ALS inhibitor herbicides for control of unwanted vegetation in ALS inhibitor herbicide tolerant beta vulgaris plants
    Patent number: 10544426
    Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: January 28, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ruediger Hain, Gerhard Johann, Guenter Donn
  • Method to develop herbicide-resistant sugar beet plants
    Patent number: 10517244
    Abstract: A method for producing herbicide-resistant sugar beet plant includes obtaining protoplasts from stomatal guard cells isolated from a sugar beet plant. A composition having an ALS herbicide is applied to the cells at a concentration which is lethal to the cells. Sugar beet plants are regenerated from the surviving cells.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 31, 2019
    Assignee: SESVANDERHAVE N.V.
    Inventors: Guy Weyens, Marc Lefebvre, Rudiger Hain, Gerhard Johann
  • ALS Inhibitor Herbicide Tolerant Mutant Plants
    Publication number: 20190136254
    Abstract: The present invention relates to an ALS inhibitor herbicide tolerant polyploid plants, such as B. napus or B. juncea plants, progeny and parts thereof comprising mutations in all acetolactase genes.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 9, 2019
    Inventors: Rene Ruiter, Rudiger Hain, Gerhard Johann, Bernd Laber